Archive for the ‘Liver Disease / Hepatitis’ Category
Monday, February 25th, 2008
Oxidative stress describes the state level of oxidative damage in a cell, tissue or organ, caused by reactive oxygen species. Alcohol induces oxidative stress in the liver resulting in an imbalance between oxidants and anti-oxidants. Increased reactive oxygen species (ROS) production and glutathione (GSH) depletion, lead to abnormal breakdown of ...
Posted in Liver Disease / Hepatitis | No Comments »
Monday, February 25th, 2008
ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, announced that it has enrolled the first patient in a disease-directed Phase II clinical trial of IMC-1121B to treat patients with advanced hepatocellular carcinoma (liver cancer). IMC-1121B, an anti-vascular endothelial growth ...
Posted in Liver Disease / Hepatitis | No Comments »
Saturday, February 23rd, 2008
HBV is tiny. The genome of this virus is a partial double stranded circle. When made fully double stranded, this genome carries about 3000 base pairs, compared to 200 kilo base pairs of the genome of the smallpox virus. These 3000 base pairs encode an envelope protein, a core protein, ...
Posted in Liver Disease / Hepatitis | No Comments »
Saturday, February 23rd, 2008
Arbios Systems, Inc. (OTC Bulletin Board: ABOS) announced that the Company has received conditional approval from the U.S. Food and Drug Administration ("FDA") of an Investigational Device Exemption ("IDE") to begin the pivotal clinical trial for SEPET(TM), Arbios' extracorporeal (outside the body) artificial liver assist device for blood purification of ...
Posted in Liver Disease / Hepatitis | No Comments »
Wednesday, February 20th, 2008
Geisinger Health System and Celera (NYSE:CRA), an Applera Corporation business, has announced that they have entered into a research collaboration with the aim of developing a diagnostic assay for the increased risk of non-alcoholic steatohepatitis (NASH). The collaboration will evaluate Celera's numerous genetic findings in liver diseases, including the Cirrhosis ...
Posted in Liver Disease / Hepatitis | No Comments »
Wednesday, February 20th, 2008
Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, is making progress in the development of its second pipeline drug, CF102, for the treatment of liver diseases and in particular liver cancer. The first dose cohort of a phase I clinical trial was successfully completed. Initiation ...
Posted in Liver Disease / Hepatitis | No Comments »
Thursday, November 1st, 2007
Roche announced that new study results for PEGASYS(R) (peginterferon alfa-2a), the world's leading treatment for chronic hepatitis C virus (HCV) infection, as well as the company's robust pipeline of hepatitis C compounds in clinical development, will be presented at the upcoming 58th Annual Meeting of the American Association for the ...
Posted in Liver Disease / Hepatitis | No Comments »
Thursday, November 1st, 2007
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) announced that the European Commission has granted marketing authorization to Nexavar(R) (sorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar, an oral anti-cancer drug, is the first approved systemic therapy for ...
Posted in Liver Disease / Hepatitis | No Comments »
Thursday, November 1st, 2007
Researchers at the Albert Einstein College of Medicine of Yeshiva University have shown for the first time that cancers can be successfully treated by targeting the viruses that cause them. The findings, published in the October 31 issue of PloS One, also raise the possibility of preventing cancer by destroying ...
Posted in Liver Disease / Hepatitis | No Comments »
